Conference
Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada
Abstract
e17000
Background: Squamous cell carcinoma of the head and neck (SCCHN) is a disfiguring and potentially fatal condition. Cetuximab is a new therapeutic option which has been shown to improve locoregional control (LRC) and reduce mortality in the treatment of locally and regionally advanced disease. Objectives: To estimate the incremental cost-utility of cetuximab plus radiotherapy (CxRT) versus cisplatin plus radiotherapy …
Authors
Sambrook J; Levy AR; Johnston KM; Ricard NJ; Bourgault C; Donato BM; Sheehan FG; Hotte SJ; Chasen MR; Briggs AH
Volume
27
Pagination
pp. e17000-e17000
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2009
DOI
10.1200/jco.2009.27.15_suppl.e17000
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X